In 2024, the diagnosed prevalent population of C3 glomerulopathy in the 7MM was approximately 5,800. This number is expected to rise through 2034, driven by advances in complement biology, improved ...

Amyndas Pharmaceuticals SA, which is committed to developing innovative therapeutics to treat complement-mediated disorders, announced today that its lead candidate, the C3 complement inhibitor ...

The complement system is an important part of the humoral immune defence in mammals that is formed by about 35 soluble and cell-surface proteins. Together these proteins enable the host to recognize ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s ...

Complement promotes inflammatory and immune responses and may affect cardiometabolic risk. This study was designed to investigate the effect of complement components C3 and C4 on cardiometabolic risk ...

The figure focuses on complement activation by means of the alternative pathway because it is the one responsible for hemolysis in PNH. The lightning bolt symbolizes the spontaneous hydrolytic ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...